Savara Inc

The Company intends to cover its future operating expenses through cash and cash equivalents on hand, short-term investments, and through a combination of equity offerings, debt financings, royalty agreements, government or other third-party funding, and other collaborations and strategic alliances with partner companies.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

Classification as short-term or long-term is based upon whether the initial maturity of the debt securities is less than or greater than twelve months, as further discussed in Note 7 .

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

Debt Facility On March 26, 2025, the Company, as borrower, entered into a Loan and Security Agreement (the Hercules Loan Agreement ) with the lenders party thereto (the Lenders ) and Hercules Capital, Inc.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The initial advance of $ 30 million under the Hercules Loan Agreement was drawn in March 2025 and used to repay all outstanding obligations under the Company s prior term loan with Silicon Valley Bank ("SVB Loan"), to pay the Company s expenses in connection with the Hercules Loan Agreement, and for general corporate purposes.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

See Note 7, Debt Facility, to the Company s Annual Report on Form 10-K for the year ended December 31, 2025 for more information regarding the Hercules Loan Agreement.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The Company assessed these features and determined the one feature related to interest due upon an event of default (the Default Penalty ) is required to be bifurcated from the debt and accounted for separately at fair value.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

US Started BLA Rolling Submission EU Completed BLA Submission BLA Resubmitted with Fuji as DS Manufacturer Potential Approval* MAA Submission Potential Approval *Assumes Priority Review is granted by the FDA UK MAA Submission Potential Approval MOLBREEVI in Autoimmune PAP Regulatory and IP Summary Savara Inc.

SEC original ↗Savara Inc — Earnings release (8-K exhibit)EX-99Jan 9, 2026

(together with its subsidiaries Savara, the Company, we or us ) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

6 The Company is currently focused on the development and regulatory approval of MOLBREEVI for the treatment of autoimmune PAP and believes such activities will result in the continued incurrence of significant research and development, regulatory, commercial and other expenses related to this program.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The Company intends to cover its future operating expenses through cash and cash equivalents on hand, short-term investments, and through a combination of equity offerings, debt financings, royalty agreements, government or other third-party funding, and other collaborations and strategic alliances with partner companies.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The Hercules Loan Agreement, as amended by the First Amendment, grants the Lenders a first-priority perfected security interest in the Company s intellectual property that will convert to a negative pledge if the Company terminates the Purchase and Sale Agreement dated October 29, 2025 with funds managed by RTW Investments, LP (the Purchase Agreement ), as further described below in Note 9.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The risks and uncertainties facing Savara are described more fully in Savara's filings with the Securities and Exchange Commission, including our filings on Form 8-K, our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

SEC original ↗Savara Inc — Earnings release (8-K exhibit)EX-99Jan 9, 2026

Legal Proceedings 26 Item 1A.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

Risks and Uncertainties The product candidate being developed by the Company requires approval from the U.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026

As a result of these and other factors and the related uncertainties, there can be no assurance of the Company s future success.

SEC original ↗Savara Inc — 10-Q Quarterly report10-QAug 11, 2026